| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9421192 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(3 years from now) | |
| US8642025 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(3 years from now) | |
| US8329159 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Jul, 2029
(5 years from now) | |
| US8629171 | BRISTOL-MYERS SQUIBB | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
Jun, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8900566 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(3 years from now) | |
Daklinza is owned by Bristol-Myers Squibb.
Daklinza contains Daclatasvir Dihydrochloride.
Daklinza has a total of 5 drug patents out of which 0 drug patents have expired.
Daklinza was authorised for market use on 24 July, 2015.
Daklinza is available in tablet;oral dosage forms.
Daklinza can be used as method of inhibiting hepatitis c virus, method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity.
Drug patent challenges can be filed against Daklinza from 25 July, 2019.
The generics of Daklinza are possible to be released after 13 June, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-727) | Feb 05, 2019 |
| New Indication(I-726) | Feb 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2020 |
| New Dosing Schedule(D-161) | Feb 05, 2019 |
| New Dosing Schedule(D-162) | Feb 05, 2019 |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
NCE-1 date: 25 July, 2019
Market Authorisation Date: 24 July, 2015
Treatment: Method of inhibiting hepatitis c virus; Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity
Dosage: TABLET;ORAL
DAKLINZA family patents
